ClinicaliQ Trial Snapshot
- Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients — Active Not Recruiting • Phase I / Phase II • Gastroenterology • NCT05234190.
- QEL-001 Trial Summary.
- A study testing a personalised cell therapy to help liver transplant patients accept their donor organ without long-term immunosuppression.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal. QEL-001 is a product made from a patients own cells, which are genetically modified and designed to help the transplant recipient's body accept their donated liver and prevent their immune system from rejecting it once immune suppression is withdrawn. Conditions: Rejection; Transplant, Liver, Liver Failure, Liver Diseases Interventions: QEL-001 Lead Sponsor: Quell Therapeutics Limited Planned Enrollment: 33 participants